Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Samantha Butzke

Pediatric Gastroenterology Annapolis, MD Medical Doctor

NPI 1780114967 CMS profile 11425840

621 Ridgely Ave Ste 201, Annapolis, MD 21401

Open in the dashboard

General payments

$5,205

258 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samantha Butzke of Annapolis, MD is reported in the CMS Open Payments database as having received $5,205 across 258 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,645 126
2024 General $1,493 77
2023 General $1,054 54
2022 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samantha Butzke
  • Pediatric Gastroenterology median
  • Middle half of Pediatric Gastroenterology
  • National median

In program year 2025, general payments to Samantha Butzke were reported at $2,645. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.

Show as a table
Year Samantha Butzke Pediatric Gastroenterology median Middle half National median
2019 $0 $131 $41–$311 $163
2020 $0 $79 $23–$223 $114
2021 $0 $104 $32–$321 $132
2022 $14 $125 $37–$331 $149
2023 $1,054 $169 $55–$440 $160
2024 $1,493 $196 $73–$563 $164
2025 $2,645 $194 $81–$540 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $741 38 payments
  2. Regeneron Healthcare Solutions, Inc. $645 32 payments
  3. Janssen Biotech, Inc. $612 28 payments
  4. Genzyme Corporation $425 17 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $298 13 payments
  6. Ardelyx, Inc. $277 11 payments
  7. Madrigal Pharmaceuticals $261 12 payments
  8. Phathom Pharmaceuticals, Inc. $247 21 payments
  9. Lilly USA, LLC $185 7 payments
  10. Ipsen Biopharmaceuticals, Inc $171 8 payments
  11. Other $1,342 71 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,205 258 payments
Products named General payments · program years 2022–2025
  1. ENTYVIO $555 25 payments
  2. XIFAXAN $443 19 payments
  3. TREMFYA $441 19 payments
  4. DUPIXENT Immunology $425 17 payments
  5. DUPIXENT Inflammation And Immunology $406 22 payments
  6. IBSRELA $277 11 payments
  7. REZDIFFRA $261 12 payments
  8. DUPIXENT Immunology And Inflammation $239 10 payments
  9. OMVOH $185 7 payments
  10. STELARA $170 9 payments
  11. Other $2,227 127 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$252,712

Of which drugs: $245,282

Medicare patients

32

Average age 74

Services billed

14,645

19 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $194
  • GENZYME CORPORATION $117
$310 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $203
$203 — —
STELARA
  • Janssen Biotech, Inc. $170
$170 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $117
$117 — —
TREMFYA
  • Janssen Biotech, Inc. $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

258 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record